Miromatrix CEO Jeff Ross to Present at the 2022 Cell & Gene Meeting on the Mesa
Miromatrix Medical (NASDAQ: MIRO) announces CEO Jeff Ross will present at the 2022 Cell & Gene Meeting on the Mesa from October 11-13.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
Miromatrix Medical (NASDAQ: MIRO) announces CEO Jeff Ross will present at the 2022 Cell & Gene Meeting on the Mesa from October 11-13. This event showcases advancements in cell therapy, gene therapy, gene editing, and regenerative medicine. Ross's presentation is scheduled for October 12 at 6:30 pm ET. Miromatrix focuses on bioengineering fully transplantable human organs, primarily targeting liver and kidney development, utilizing a proprietary perfusion technology platform to combat organ shortages.
Details
News Market Reaction – MIRO
The recorded move for MIRO in the trading session of this news was +3.93%.
Data tracked by StockTitan Argus. Session date unavailable.
AI-generated analysis. How Rhea-AI works. Not financial advice.
EDEN PRAIRIE, Minn., Oct. 05, 2022 (GLOBE NEWSWIRE) -- Miromatrix Medical Inc. (NASDAQ: MIRO), a life sciences company pioneering a novel technology for bioengineering fully transplantable organs to help save and improve patients' lives, today announced that CEO Jeff Ross will present at the 2022 Cell & Gene Meeting on the Mesa. The three day event held this year on October 11-13 features in-person and pre-recorded virtual presentations by leading public and private companies highlighting technical and clinical achievements over the past 12 months in the areas of cell therapy, gene therapy, gene editing, tissue engineering, and regenerative medicine.
Mr. Ross will deliver his remarks at the 2022 Cell & Gene Meeting on the Mesa in the Oxford Biomedica Ballroom on October 12th, 2022 at 6:30 pm ET. Registration for the conference is available here.
About Miromatrix
Miromatrix Medical Inc. is a life sciences company pioneering a novel technology for bioengineering fully transplantable human organs to help save and improve patients' lives. The Company has developed a proprietary perfusion technology platform for bioengineering organs that it believes will efficiently scale to address the shortage of available human organs. The Company's initial development focus is on human livers and kidneys. For more information, visit miromatrix.com.
Investor Contact
Greg Chodaczek
347-620-7010
ir@miromatrix.com
Media Contact:
press@miromatrix.com
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.